Our mission is to expand and expedite the discovery and development of new cancer therapeutic agents based on novel insights into cancer biology.
We focus on the early stages of the drug discovery process, from target validation through “proof-of concept” studies, which seek to demonstrate that a newly discovered drug candidate can successfully alter the course of cancer disease progression.
We combine the strengths and resources of faculty with complementary expertise in assay development, high-throughput screening, downstream medicinal chemistry and pharmacology through our partnership with the Conrad Prebys Center for Chemical Genomics.
Director’s Statement
“Through cross-program, early translational efforts, we leverage novel findings to identify and validate new targets for cancer, develop small molecule compounds that modify or control identified targets and test potential drug candidates in state-of-the-art animal, computational and in vitro models of cancer.”
Sanghvi N, Calvo-Alcañiz C, Rajagopal PS, Scalera S, Canu V, Sinha S, Schischlik F, Wang K, Madan S, Shulman E, Papanicolau-Sengos A, Blandino G, Ruppin E, Nair NU
